


## Supplemental Material

### A slit-diaphragm-associated protein network for dynamic control of renal filtration

Maciej K. Kocylowski, Hande Aypek, Wolfgang Bildl, Martin Helmstädter, Philipp Trachte, Bernhard Dumoulin, Sina Wittösch, Lukas Kühne, Ute Aukschun, Oliver Kretz, Botond Gaal, Akos Kulik, Corinne Antignac, Geraldine Mollet, Anna Köttgen, Burulca Göcmen, Jochen Schwenk, Uwe Schulte, Tobias B. Huber, Bernd Fakler and Florian Grahammer

- Supplementary Figures 1 – 9


**Supplementary Figure 1 (information related to Figure 1)**



**Supplementary Figure 1**  
**Characterization of glomerular membrane fractions**

(A), Denaturing gel separation of the protein fractions obtained during preparation of the glomerular ‘membrane fraction’ (MF) used for meAPs Western-probed for the indicated proteins. The alpha1-subunit of the Na-K-ATPase was used a marker for plasma membrane proteins. Experiment was repeated at least four times. (B), Abundance of all proteins determined by MS-analysis in two independent preparations of the MF-fraction. Note enrichment of the SD core components in either preparation.

## Supplementary Figure 2 (information related to Figures 1, 2)




target	no.	supplier	cat. No.	epitope/antigen	source	efficiency
<b>Nephrin</b>	<b>a1</b>	Progen	GP-N2	1243-1256	Progen	1.00
<b>Nephrin</b>	<b>a2</b>	R&D Systems	AF3159	37-1049	R&D Systems	0.70
Nephrin	a3	Santa-Cruz	sc19000	N-terminus	Santa-Cruz	0.07
Nephrin	a4	Santa-Cruz	sc28192	23-322	Santa-Cruz	0.00
Nephrin	a5	AbFrontier	pep3+6	491-509/1053-1073	this study	WB -
<b>Neph1</b>	<b>a1</b>	Pineda		767-788	Grahammer et al.	1.00
Neph1	a2	AbFrontier	pep3	658-678	this study	0.48
Neph1	a3	AbFrontier	R2	365-387/658-678	this study	0.12
Neph1	a4	AbFrontier	R1	365-387/658-678	this study	0.10
Neph1	a5	AbFrontier	pep1	365-387	this study	0.01
<b>Podocin</b>	<b>a1</b>	sigma	P0372	367-383	sigma	1.00
<b>Podocin</b>	<b>a2</b>	AbFrontier	pep1	34-47	this study	0.54
Podocin	a3	AbFrontier	pep3	354-368	this study	0.17
Podocin	a4	AbFrontier	C-term R1	135-383	Roselli et al.	0.07
Podocin	a5	AbFrontier	R1	34-47/354-368	this study	0.05
Podocin	a6	AbFrontier	R2	34-47/354-368	this study	0.01
Podocin	a7	AbFrontier	C-term R2	135-383	Roselli et al.	WB+
Podocin	a8	AbFrontier	C-term R3	135-383	Roselli et al.	WB+

### Supplementary Figure 2 Characterization of antibodies

Epitope-localization and characterization of ABs against the SD core components Nephrin, Neph1 and Podocin. The ABs highlighted in bold for each target were finally used for the meAPs reported in this work. Efficiency reflects the relative abundance of the respective target protein in APs determined by MS-analysis and normalized to the best performing AB. WB +/- indicates that antibody efficiency was tested only by AP-WB.

### Supplementary Figure 3 (information related to Figures 1, 2)



### Supplementary Figure 3

#### Solubilization efficiency and gel separation of CL-91 solubilized membrane fractions

(A), SDS-PAGE separation of unsolubilized (T) and CL-solubilized (S) membrane fractions Western-probed for the indicated SD core constituents; MW scaling as indicated. Experiment was at least five times. (B), Two-dimensional gel separation of CL-91 solubilized membrane fractions prepared from isolated rat glomeruli, Western-probed with ABs against the indicated proteins. Apparent molecular mass (native PAGE, 1<sup>st</sup> dimension) and molecular weight (denaturing SDS-PAGE, 2<sup>nd</sup> dimension) are indicated; gel separations were repeated twice with similar results.

### Supplementary Figure 4 (next page, information related to Figures 1, 2)

#### Coverage of primary sequences and phosphorylation status of the indicated SD core components derived from MS/MS-identified peptides

Left panel: Peptides identified by mass spectrometry are in red; those accessible to but not identified in MS/MS analyses are in black, and peptides hardly or not accessible to our MS/MS analyses used are given in grey. Phosphorylated residues are highlighted in yellow; transmembrane segment is indicated by a line.

Right panel: Exemplary MS/MS spectra (b- and y-ion series) of the indicated phosphorylated peptides of Nephrin (top), Neph1 (middle) and Podocin (bottom).


Note the 'triple phosphorylation' occurring in the 'acidic cluster' C-terminal to the transmembrane domain of Nephrin.

**NPHN\_RAT (Q9R044) - Nephrin**

Coverage is 45.4% absolute, 64.2% relative.

```

0001 MGAARVTVRG ARTSPIHRMS SLTFLLMGM LTSGLAESPV PTSAPRGFWA
0051 LSENLTAVEG TTVKLCWCVR APGSVVQNAK DGLLLGPNPK MPGFPRYSLE
0101 GDRAKGEFHL LIEACDLSDD AEYECQVGRS ELGPVLVSPK VILSILVSPK
0151 VLLLTPEAGS TTVTWAGQEQ VVTCVSGDAK PAPTITFIQS GRITLDVSSN
0201 VNEGSEKLC TTEAEARVIP QSSDNGQLLV CEGSNPALDT PIKASFTMNI
0251 LFFPFPFVID WFGLNEGHVR AGENLELPTC ARGGNPPATL QWLKNGKRVPS
0301 TAWGTEHAQA VAHSVIVMTV RPDDEGALLS CQSYNSVSAG TQERSITLQV
0351 TFFPSAITLL GSVSQSENKN VTLCCLTRSS RFRVLLRWLW GGRQLLEPDE
0401 TVMDGLHGHH ISMSNLTFVL REDNGPLPT CAFSDAFSK ETFKSLTLN
0451 VKYPAQKLMV EGPPEGQYIR TGTNRVRLVCL AIGGNPDPFL IWFKDSRPVS
0501 EPRQPQEPFR VQLGSVEKSG STFSRELVLI IGPDPNRAKF SCKAGQLSAS
0551 TQLVVQFPPT NLTILANSSA LRPGDALNLT CVSISSNPFV NLSWDRKEGER
0601 LEDVAAPKPS AEFKGSAAAR SVFLRVSSRD HGQRVTCRAH SEALRETVSS
0651 FYRFNVLYPP EFLGQVRAV TVVEQGQVLL PVSVANPAP EAFNWTFRGY
0701 RLSPAGGPRH RILSGGALQL WNVTRADDGF YQLHCQNSG TAEALLKLDV
0751 HYAPTIRALR DPEFVNVGGS VDIVCTVDAN PILPEMFSWE RLGEEDLDN
0801 LDDMEKVSAG STGRLRIRQA KLSQAGAYQC IVDNGVAPA RGLVRLVRFV
0851 APQVDQPTFL TKVAAGDST SSATLHCRAR GVPNIDFTWT KNGVPLDLQV
0901 FRYTEHRHQ GVVHSLTI ANVSAQDYA LFKCTATNAL GSDHTNIQLD
0951 SISRPDPFLG LKVVVISPHS VGLEWPKGFD GGLPQRFPQIR YEALTEPGFL
1001 HVDVLPQAT TFFLTGLKPS TRRIWLLAS NALGDSGLDT KGIQVSVTTP
1051 GPDQAPEDTD HQLPTELEPPG PPLLPLELVL FAVGGLLLS NASCVGGLW
1101 RRRLRLAEE ISEKTRAGS DRIRNEYES QWTGDRDTS STVSTAEDVP
1151 NYYSMRDPS QLPFTLEEVV YHQARGEDM AFPGLHDEV ERAIYPPGAN
1201 GPLYDEVMD PYDLRWPEVQ CEDPRGIYDQ VAAMDAVEA SLLPFELRGH
1251 LV
  
```




**KIRRI\_RAT (Q6X936) - Kin Of IRE-like Protein 1**

Coverage is 49.9% absolute, 68.9% relative.

```

0001 MTLERNSTCL MTCQSSLLPK KPRFLSQRMW APHLVVAYLI FVTLALALPG
0051 TQTRFSQEPA DQTVVAGHRA VLPCLVLLNYS GIVQWTKDGL ALGGMQGLKA
0101 WPRYRVVGS DAQVNLBIT DAELSDDASY ECQATEAALR SRRAKLTVLI
0151 PFDTRIDGG FVILLQAGTP YNLTCRAFNA KPAATIIFWR DGTQEGAVT
0201 STELLKDRGR ETTISQLLIQ PTDLDIGRVF TCRSMNEAIP NGKETSIELD
0251 VHHPTPTLIS IEPQVLEGE SVIFTCQATA NEFLIGYRWA KGGFLIEDAH
0301 ESRYSITNDY SFTFPEVSC EYINKVSQTNV STLVNHFAP RLIVVYKPTT
0351 TDIGSDVTLT CVNVGNPELT LTFWFKKDSNM VLSNSQLLL KSVTQADAGT
0401 YTCRAIVPRI GVAEREVFLV VNGPPIISSE AVQFAVRGDD GKVECFIGST
0451 PPDRIAWAN KENFLEVGLT ERYTVERTNS GSVLSTLTI NNVMEDFQT
0501 HYNCTAWNSF GPOTAIQLE EREVLPVGI IAGATIGAGIL LVFSFAALVF
0551 FLKRRRKGSR KDVLTKRLDI KVETVNRPEL TMHSDREDDT TSISTATPRM
0601 KAIYSPKDD VDKQLDLC D TIEETREYEM KDPNTGYNV RAHEDRFVS
0651 AVLYADYRAP GPTRFDGRPS SRLSHSSGYA QLNTYSRAPA SDYGTETPS
0701 GPSAPGGTDT TSQLSYENVE KFNSHFPFGA AGYPTYRLGY PQAPPSGLER
0751 TPYEAYDPFG KYATATRFYS TSQHSBYGQR FQQRMQTHV
  
```




	undetectable	indirectly findable	findable
found		SEQUENCE	SEQUENCE
not found	SEQUENCE	SEQUENCE	SEQUENCE

**PODO\_MOUSE (Q91X05) - Podocin**

Coverage is 65.5% absolute, 91.6% relative.


```

0001 MDSRARSSSR EAHGRSSRS SRDDKAKAG RGRSGRARP D AGAERQSTGR
0051 TATRGEPRAP AATATVVDVD EVRGPGEET EVVALLESER PEEGKPSGL
0101 GACBLLVLA SLIFIMTFE FSIWFCIEVV QEYERVIIFR LGHLLPGRK
0151 GPGLEFFLPC LDTYHKVDLR LQTLIEPFHE VVTKDMFIME IDAVCYRME
0201 NASLLSSLA HVSKAIQFLV QTMKRLAH RSLTEILLER KSIAQDVKVA
0251 LDAVTCIWI KVERTEIKDV RLPAGLQHS L AVEAEAQRQA KRVVIAAEGE
0301 KAASELRMA AEILSGTFAA VQLRYLHTLQ SLSTEKPATV VLPLPFDMLS
0351 LSSSPGNRAQ GSINYPSSSK VPEPLNPKK DSPML
  
```



Supplementary Figure 4

## Supplementary Figure 5 (information related to Figures 1, 2)



## Supplementary Figure 5


### Target-normalization of protein abundance ratios in APs versus control

Upper panel: Formula used for calculating tnR from respective protein ratio, target protein ratio and the mean of background protein ratios in log space. Lower panel: Histogram illustrating an example distribution of protein ratios in AP vs control (arbitrary values) together with the determination of the specificity threshold (tnR = 0.25). Distribution of ratios determined for background proteins is indicated by a blue line (fit of a Gaussian distribution, peak close to 0 in log space), the ratio of the AP target protein is given by the triangle in green. Note that normalization of protein ratios is prerequisite for direct comparison of results from APs with different antibodies and control IgGs.

## Supplementary Figure 6 (next page, information related to Figure 3)

### Characterization of glomeruli and podocytes in *Nphs1* <sup>$\Delta$ iPod</sup>, *Nphs2* <sup>$\Delta$ iPod</sup> and *Neph1* <sup>$\Delta$ iPod</sup> knockout mice

(A), Immuno-staining of podocytes (from three animals each) for Neph1, Neph1 and Podocin (left panels), PAS-staining of kidney tissue and EM analysis of FPs in wildtype (control), *Nphs1* <sup>$\Delta$ iPod</sup> and *Neph1* <sup>$\Delta$ iPod</sup> knockout mice 4 weeks after induction by doxycycline. *Nphs1* <sup>$\Delta$ iPod</sup> showed no changes in immuno-staining pattern nor in glomerulus morphology compared to wildtype. In *Neph1* <sup>$\Delta$ iPod</sup> mice Neph1-staining was slightly reduced at unchanged PAS staining, podocyte FPs appeared widely flattened in line with the pronounced albuminuria (Fig. 3B). (B), In *Nphs2* <sup>$\Delta$ iPod</sup> mice immuno-staining (from three animals each) was reduced for all three SD core proteins, PAS stain indicated segmental loss of the glomerular tuft with extensive synechia of Bowman's capsule. In addition, the FPs were largely flattened correlating with the massive albuminuria (Fig. 3C).




## Supplementary Figure 6

## Supplementary Figure 7 (next page, information related to Figure 3)

### Alterations in the SD-associated network following induced knock-down of the SD core-components

Protein abundances were determined in (unsolubilized) total membrane fractions by mass spectrometry.

(A), Abundance ratios (log<sub>10</sub>) determined for the indicated constituents of the Nephrin interactome (relative to controls (without doxycycline administration, 'WT') at distinct periods (1 week (green), 6 weeks (purple) and 12 weeks (orange)) after induction of Nephrin KO (Nphs1<sup>ΔiPod</sup>). (B), Abundance ratios as in the top panel determined 4 weeks after induction of Neph1 KO (Neph1<sup>ΔiPod</sup>). (C), Abundance changes determined for the indicated constituents of the Podocin interactome 2 weeks after induction of Podocin KO (Nphs2<sup>ΔiPod</sup>). (D), Overlay of the changes determined for the common SD-core interactors at the indicated time points after KO induction. Note consistency and interdependence in stability of these SD constituents.




## Supplementary Figure 7

## Supplementary Figure 8 (next page, information related to Figure 3)

### Changes in Nephrin phosphorylation after induction of its knock-down

Results from total membrane analysis (Fig. S7) were inspected for changes in intensity of peptides derived from the C-terminal phosphorylation cluster of Nephrin (Fig. S4, sequence RLAEELSEKTEAGSEEDRLR) 1 and 6 weeks after induction of Nephrin KO ('KO'). Control was without induction ('WT'). (A), Abundance ratios as in Fig. S7 for the indicated non-phosphorylated ('non-phospho') and phosphorylated ('phospho') peptides (phosphorylated residues highlighted in red). (B), Changes in Nephrin phosphorylation determined by comparing MS-intensity of the indicated phosphorylated peptide species to its non-phosphorylated counterpart in the indicated datasets. Note the roughly 2-fold increase in relative phosphorylation upon induction of Nephrin KO for all three sites/peptides.





## Supplementary Figure 8



Supplementary Figure 9 (next page, information related to Discussion)

## Supplementary Figure 9

### Enrichment of interactomes with genes causing kidney phenotypes in humans and mice

(A), Intersection plot showing overlap between genes in the interactomes determined for Nephrin/Neph1 and Podocin with genes known to cause four different kidney phenotypes in genetically manipulated mice (based on MGI database, <http://www.informatics.jax.org/>, accessed on July 14, 2021). Genes implicated in abnormal kidney morphology, kidney physiology, and urine protein level were found to be significantly enriched in the Podocin interactome. (B), Intersection plot as in (A) but performed with genes known to cause four different subtypes of monogenic kidney disease in humans (based on <sup>1</sup>). Genes implicated

in glomerular kidney disease were found to be significantly enriched in the Podocin interactome. One sided Fisher's exact test was performed in R to test for enrichment of the different gene lists assuming 20,000 total protein-coding genes and a p-value threshold of  $0.05/8 = 6.25E-03$  to account for multiple testing. Confidence intervals for the odds ratios were computed using the `exact2x2` package with `tsmethod="minlike"` (doi: 10.1093/biostatistics/kxp050). The p-value and odds ratio for each test is in the table, with significant results shown in bold. Odds ratios and p-values are N.A. if no overlap exists. Genes that are common between interactome lists and various kidney phenotype gene lists are labeled with the gene symbol. As negative controls we used genes related to brain size (414 unique genes) and respiratory system development (167 unique genes).



## References

1. Rasouly, H.M. *et al.* The Burden of Candidate Pathogenic Variants for Kidney and Genitourinary Disorders Emerging From Exome Sequencing. *Ann Intern Med* **170**, 11-21 (2019).